Shares of SI-BONE, Inc. (SIBN) are soaring 15.79% in intraday trading on Tuesday, following the release of the company's stellar first-quarter 2025 financial results. The medical device maker, specializing in minimally invasive surgical devices for the sacroiliac joint, significantly outperformed Wall Street expectations on both earnings and revenue fronts.

SI-BONE reported a quarterly adjusted loss of $0.15 per share, substantially better than the average analyst estimate of a $0.23 loss per share. The company's revenue surged 24.9% year-over-year to $47.29 million, surpassing the Street forecast of $45.17 million. This marks the fourth consecutive quarter that SI-BONE has beaten earnings estimates, showcasing consistent operational improvement.

The strong quarterly performance has prompted several analysts to revise their outlook on the stock. Citizens JMP analyst David Turkaly reiterated a Buy rating with a price target of $32.00, while Truist Securities raised its target price to $22 from $20. Needham and Cantor Fitzgerald maintained their price targets at $24.00 and $25.00 per share, respectively. The current average analyst rating on SI-BONE shares is "buy," with all 9 analysts covering the stock recommending either "strong buy" or "buy." This positive sentiment, coupled with the company's impressive financial results, has fueled today's significant stock price surge, reflecting growing investor confidence in SI-BONE's future prospects within the medical equipment and supplies sector.